Exact Sciences Corporation (EXAS)

NASDAQ: EXAS · IEX Real-Time Price · USD
-0.25 (-0.37%)
Mar 30, 2023, 10:40 AM EDT - Market open
Market Cap 11.98B
Revenue (ttm) 2.08B
Net Income (ttm) -623.51M
Shares Out 179.23M
EPS (ttm) -3.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 151,987
Open 67.61
Previous Close 67.11
Day's Range 66.59 - 67.88
52-Week Range 29.27 - 76.94
Beta 1.42
Analysts Buy
Price Target 77.76 (+16.3%)
Earnings Date Apr 25, 2023

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX... [Read more]

Sector Healthcare
Founded 1995
Employees 6,420
Stock Exchange NASDAQ
Ticker Symbol EXAS
Full Company Profile

Financial Performance

In 2022, Exact Sciences's revenue was $2.08 billion, an increase of 17.95% compared to the previous year's $1.77 billion. Losses were -$623.51 million, 4.68% more than in 2021.

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $77.76, which is an increase of 16.30% from the latest price.

Price Target
(16.30% upside)
Analyst Consensus: Buy
Stock Forecasts


3 Stocks With Superior Potential for Super-Sized Gains in 2023

Stocks with potential are probably not everyone's cup of tea right now. With talks of an impending recession, everyone is looking for safer options.

Other symbols: CRMV
1 week ago - InvestorPlace

Cathie Wood Is Betting Big on These 5 AI Stocks

Love it or hate it, tech investing is back on the menu in 2023. As a result, Cathie Wood's back in the limelight.

1 month ago - InvestorPlace

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

MADISON, Wis. , Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 202...

1 month ago - PRNewsWire

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

1 month ago - Zacks Investment Research

Exact Sciences to participate in March investor conferences

MADISON, Wis. , Feb. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate...

1 month ago - PRNewsWire

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Exact Sciences Announces Fourth Quarter 2022 Results

Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022  highlights Total fourth quarter revenue of $553 million, an inc...

1 month ago - PRNewsWire

5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week

The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.

Other symbols: GFLLECONITECK
1 month ago - Zacks Investment Research

Why Earnings Season Could Be Great for Exact Sciences (EXAS)

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

1 month ago - Zacks Investment Research

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Other symbols: IARTMDT
1 month ago - Zacks Investment Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

1 month ago - Zacks Investment Research

Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.

Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer MADISON, Wis. , Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS),...

1 month ago - PRNewsWire

Is Biotech Immunocore About To Make A 25% Price Move?

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc...

1 month ago - MarketBeat

Cathie Wood Is Doubling Down on This Hidden-Gem Artificial Intelligence Stock

In November 2021, Cathie Wood described artificial intelligence as the “next big frontier” of the tech sector. Roughly a year later, OpenAI released advanced chatbot ChatGPT, and almost overnight, the...

1 month ago - InvestorPlace

Exact Sciences schedules fourth quarter 2022 earnings call

MADISON, Wis. , Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fou...

2 months ago - PRNewsWire

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Cathie Wood Is Buying These Stocks, Should You?

Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying.

Other symbols: TSLAZM
2 months ago - MarketBeat

3 Top Stocks Already up More Than 20% In 2023

While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue?

Other symbols: AALJKS
2 months ago - Zacks Investment Research

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

2 months ago - Zacks Investment Research

Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla

Shares of Exact Sciences, Inc. EXAS have been on a tear, having gained over 27% in two sessions this week.

2 months ago - Benzinga

Exact Sciences Corp Stock Price Is Trending Up Here's Why

Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.

2 months ago - MarketBeat

Cathie Wood's Top 5 Stocks See Abysmal Year in 2022

As we head into a new year, investors are taking a look at their portfolios to determine which stocks were winners and losers in 2022.

2 months ago - GuruFocus

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

2 months ago - Zacks Investment Research